Great to see a firm number, 60m per annum. Current orders may be supplied from their current stock of 6m units.
"Glaxo said it was set to produce 5 million treatment packs of Relenza a month within the next 12 to 14 weeks, equivalent to an annual run rate of 50-60 million."
"The British company said it currently had 6 million packs of existing Relenza stock and was prioritising orders to governments, a number of which are supplementing their stockpiles of antivirals because of the imminent threat of a pandemic."